Pacira BioSciences, Inc. 8-K

What Happened
Pacira BioSciences, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company furnished the full press release announcing those results as Exhibit 99.1 to its Current Report on Form 8‑K filed February 26, 2026.

Key Details

• The 8‑K was filed on February 26, 2026 under Item 2.02 (Results of Operations and Financial Condition).
• The press release containing the Q4 and full‑year 2025 results is attached as Exhibit 99.1 to the filing.
• The filing also includes the Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.
• The report was signed by Kristen Williams, Chief Administrative Officer and Secretary.

Why It Matters
Earnings releases provide the core figures investors use to assess recent sales, profitability, and trends; this 8‑K notifies the market that Pacira’s Q4 and full‑year 2025 results are now public. Retail investors should review the attached press release (Exhibit 99.1) for revenue, net income (or loss), EPS, and any management commentary or guidance that could affect the stock or near‑term outlook.